Insider Buying: Neoleukin Therapeutics (NASDAQ:NLTX) Director Acquires 371,525 Shares of Stock

Neoleukin Therapeutics (NASDAQ:NLTX) Director Bros. Advisors Lp Baker acquired 371,525 shares of Neoleukin Therapeutics stock in a transaction dated Wednesday, August 7th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $1,114,575.00.

Shares of NLTX traded up $0.23 during trading hours on Monday, hitting $2.88. The company had a trading volume of 10,890 shares, compared to its average volume of 170,063. Neoleukin Therapeutics has a 52-week low of $2.00 and a 52-week high of $4.23.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.

Read More: Relative Strength Index

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.